BioCryst Pharmaceuticals, Inc. (BCRX)
Stock Price Chart
Key Info
| Market Cap | 698.55M |
| Revenue (ttm) | 49.19M |
| Net Income (ttm) | -116.42M |
| Shares Out | 176.43M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 12, 2020 |
| Last Price | $3.96 |
| Previous Close | $3.96 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 3.99 |
| Day's Range | 3.93 - 4.07 |
| Day's Volume | 1,606,662 |
| 52-Week Range | 1.38 - 6.29 |
More Stats
| Market Cap | 698.55M |
| Enterprise Value | 592.44M |
| Earnings Date (est) | Nov 10, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 176.43M |
| Float | 154.93M |
| EPS (basic) | -0.8 |
| EPS (diluted) | -0.84 |
| FCF / Share | -0.57 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 32.10M |
| Short Ratio | 3.64 |
| Short % of Float | 18.95% |
| Beta | 2.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 14.20 |
| PB Ratio | 192.00 |
| Revenue | 49.19M |
| Operating Income | -114.70M |
| Net Income | -116.42M |
| Free Cash Flow | -92.76M |
| Net Cash | 106.11M |
| Net Cash / Share | 0.60 |
| Gross Margin | -126.71% |
| Operating Margin | -233.15% |
| Profit Margin | -236.70% |
| FCF Margin | -188.55% |
| ROA | -49.79% |
| ROE | -882.75% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.84 | 20.65 | 25.19 | 26.35 | 48.26 | 13.61 | 17.33 | 26.29 | 19.64 | 62.38 |
| Revenue Growth | 136.45% | -18% | -4.43% | -45.39% | 254.62% | -21.48% | -34.09% | 33.85% | -68.51% | - |
| Gross Profit | 44.73 | 20.18 | 23.48 | 23.65 | 46.36 | 13.49 | 17.23 | 26.16 | 19.64 | 62.30 |
| Operating Income | -99.46 | -94.22 | -57.41 | -48.61 | -39.44 | -45.77 | -30.72 | -33.89 | -49.59 | -34.36 |
| Net Income | -109 | -101 | -65.78 | -55.14 | -43.02 | -45.19 | -30.11 | -39.08 | -56.95 | -33.85 |
| Shares Outstanding | 116 | 103 | 84.45 | 73.70 | 72.90 | 66.77 | 55.22 | 49.47 | 45.14 | 44.56 |
| Earnings Per Share | -0.94 | -0.98 | -0.78 | -0.75 | -0.59 | -0.68 | -0.55 | -0.79 | -1.26 | -0.76 |
| Operating Cash Flow | -89.58 | -92.57 | -41.14 | -53.44 | -13.12 | -38.55 | -26.53 | -37.40 | -32.25 | -28.56 |
| Capital Expenditures | -0.34 | -0.37 | -0.32 | -5.27 | -5.12 | -0.11 | 0.02 | -0.11 | -0.06 | -0.33 |
| Free Cash Flow | -89.93 | -92.93 | -41.46 | -58.71 | -18.24 | -38.66 | -26.51 | -37.51 | -32.31 | -28.88 |
| Cash & Equivalents | 138 | 106 | 118 | 56.20 | 53.18 | 72.92 | 38.21 | 35.91 | 42.34 | 54.57 |
| Total Debt | 84.65 | 61.82 | 54.72 | 53.72 | 30.18 | 30.00 | 30.00 | 30.00 | 30.00 | - |
| Net Cash / Debt | 53.12 | 44.19 | 62.96 | 2.47 | 23.00 | 42.92 | 8.21 | 5.91 | 12.34 | 54.57 |
| Assets | 175 | 147 | 178 | 89.85 | 122 | 137 | 48.87 | 57.44 | 82.21 | 109 |
| Liabilities | 137 | 97.61 | 94.49 | 88.27 | 74.64 | 61.24 | 49.99 | 57.89 | 67.40 | 43.94 |
| Book Value | 38.25 | 49.24 | 83.77 | 1.58 | 47.72 | 75.64 | -1.13 | -0.45 | 14.81 | 65.50 |
Company Profile
Company Details
| Full Name | BioCryst Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 140 |
| CEO | Jon P. Stonehouse |
Stock Information
| Ticker Symbol | BCRX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: BCRX |
| IPO Date | March 3, 1994 |
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.